Viking Therapeutics (XTER:1VT) 6-1 Month Momentum %: N/A% (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:1VT Viking Therapeutics Inc XTER:1VT
34 GF Score
Price €28.30
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics 6-1 Month Momentum %?

Viking Therapeutics XTER:1VT -3.90% 34 6-1 Month Momentum % is N/A% as of Aug. 24, 2026. GuruFocus rates XTER:1VT with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,382 Biotechnology companies, Viking Therapeutics ranks better than 80.54% on this metric.

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-24), Viking Therapeutics's 6-1 Month Momentum % is N/A%.

The industry rank for Viking Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

XTER:1VT's 6-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -14.29
* Ranked among companies with meaningful 6-1 Month Momentum % only.

Viking Therapeutics  (XTER:1VT) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Viking Therapeutics 6-1 Month Momentum % Related Terms

XTER:1VT
34GF Score
Viking Therapeutics Inc XTER:1VT
6-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics  (XTER:1VT) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-1 Month Momentum % →
What does a 6-1 Month Momentum % of N/A% mean?
Viking Therapeutics (XTER:1VT) has a 6-1 Month Momentum % of N/A% as of Aug. 24, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Viking Therapeutics and its competitors. According to the industry distribution chart, Viking Therapeutics ranks #269 out of 1382 companies in the Biotechnology industry, placing it in the top 19.5%.
Is Viking Therapeutics' 6-1 Month Momentum % too high?
Viking Therapeutics' current 6-1 Month Momentum % is N/A%. Based on the distribution chart, Viking Therapeutics ranks #269 out of 1382 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Viking Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' 6-1 Month Momentum % compare to ?
According to the Biotechnology industry distribution chart, Viking Therapeutics ranks #269 out of 1382 companies for 6-1 Month Momentum %. This places Viking Therapeutics in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Viking Therapeutics and its competitors. Viking Therapeutics's current 6-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (XTER:1VT) has a current 6-1 Month Momentum % of N/A%. The current 6-1 Month Momentum % is N/A%. Viking Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Viking Therapeutics (XTER:1VT), the current 6-1 Month Momentum % is N/A% as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viking Therapeutics Business Description

Comparable Companies
Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
34GF Score

Get the complete analysis for XTER:1VT

6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.30
Price